RxDoctor Payments Data

Gwenn Leatherman

Family · Hagerstown, MDNPI 1164875654

Payments from drug & device makers

$1,097in general payments, 2019–2025

Across 25 payments — averaging $43.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$247
  • Lilly USA, LLC$179
  • Corium, LLC$126
  • Axsome Therapeutics, Inc.$125
  • Viiv Healthcare Company$123
  • AstraZeneca$123
  • plus $173 from 5 others

What the payments were for

  • Food & beverage$1,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,097 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$55,849
Medicare patients
182
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$45,144
MounjaroTirzepatide32$36,071
RybelsusSemaglutide15$18,751
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,389
VascepaIcosapent Ethyl11$4,077
Atorvastatin Calcium87$1,598
SynthroidLevothyroxine Sodium29$1,127
Pantoprazole Sodium64$907
Albuterol Sulfate HfaAlbuterol Sulfate27$835
Rosuvastatin Calcium44$818
Levothyroxine Sodium91$707
Famotidine65$704
Simvastatin86$673
Lisinopril85$633
Amlodipine Besylate93$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$57$63,89646 claims
Lilly USA, LLCMounjaro$179$36,07132 claims
GSKAnoro Ellipta$39$4,38912 claims
AbbVieSynthroid$33$1,12729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →